The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Open accessAbstract
The rise of drug resistance in cancer cells presents a formidable challenge in modern oncology, necessitating the exploration of innovative therapeutic strategies. This review investigates the latest advancements in overcoming drug resistance mechanisms employed by cancer cells, focusing on emerging therapeutic modalities. The intricate molecular insights into drug resistance, including genetic mutations, efflux pumps, altered signaling pathways, and microenvironmental influences, are discussed. Furthermore, the promising avenues offered by targeted therapies, combination treatments, immunotherapies, and precision medicine approaches are highlighted. Specifically, the synergistic effects of combining traditional cytotoxic agents with molecularly targeted inhibitors to circumvent resistance pathways are examined. Additionally, the evolving landscape of immunotherapeutic interventions, including immune checkpoint inhibitors and adoptive cell therapies, is explored in terms of bolstering anti-tumor immune responses and overcoming immune evasion mechanisms. Moreover, the significance of biomarker-driven strategies for predicting and monitoring treatment responses is underscored, thereby optimizing therapeutic outcomes. For insights into the future direction of cancer treatment paradigms, the current review focused on prevailing drug resistance challenges and improving patient outcomes, through an integrative analysis of these emerging therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Activation of survival pathways can promote cell survival and proliferation in the presence of DNA-damaging agents [49].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CRC cells often have enhanced DNA damage repair capacity due to upregulation of alternative pathways and can fix DNA damage induced by chemotherapy or radiotherapy [49].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ICIs like pembrolizumab and nivolumab block the PD-1 receptor, which activates T cells and allows them to better recognize and destroy tumor cells, even those that have become resistant to other treatments [49].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By inhibiting PARP, these drugs block the repair of single-strand breaks, leading to the accumulation of double-strand breaks and cell death [49].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“combining cytotoxic chemotherapy drugs with molecular-targeted inhibitors can have synergistic effects that circumvent resistance pathways [49].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [49]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“This binding makes the T cells ineffective, leading to immune evasion and exhaustion [79].”
BackgroundAn overview of clinical decision support systems: Benefits, risks, and strategies for success
Sutton, R. T., Pincock, D., Baumgart, D. C., Sadowski, D. C., Fedorak, R. N., & Kroeker, K. I. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-0221-y · Cited by 3,019 · cited 1×
“Keeping up with the fast pace of cancer research and technology is also a challenge [118].”
BackgroundZhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794 · cited 1×
“One major area of progress involves uncovering the molecular pathways linked to drug removal from cells [15].”
BackgroundCombination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543 · cited 1×
“Combination therapies enhance anticancer effects and overcome resistance by simultaneously targeting multiple signaling pathways [35].”
BackgroundDrug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463 · cited 3×
“This makes it harder to treat or control the growth of tumors [1].”
BackgroundCTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360 · cited 1×
“Cancer cells can exploit these pathways to evade immune detection and destruction [71].”
BackgroundRoles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111 · cited 1×
“The immune system’s ability to recognize and target cancer cells is based on the recognition of specific antigens or markers expressed by tumor cells, which distinguishes them from normal cells [67].”
BackgroundMechanisms of DNA damage, repair, and mutagenesis
Chatterjee, N., & Walker, G. C. (2017) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22087 · Cited by 2,039 · cited 1×
“Furthermore, the nucleotide excision repair (NER) pathway and the base excision repair (BER) pathway contribute to rectifying diverse forms of DNA damage induced by chemotherapeutic agents [26].”
BackgroundThe Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
Cited by
Understanding and overcoming multidrug resistance in cancer
Ge, M., Chen, X.-Y., Huang, P., Fleishman, J. S., Yang, D., Wu, Z., Ke, Z., & Chen, Z. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01059-1 · Cited by 167
“…might uncover clinically relevant resistance mechanisms that emerge during therapy, thereby improving our understanding of MDR. Efforts to overcome MDR in clinical settings have largely focused on combination therapies, developing novel anticancer agents and enhancing drug delivery methods 323 .”
Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment
Garg, P. K., Pareek, S., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216537 · Cited by 149
“To overcome resistance, integrating immunotherapy with other treatment modalities such as targeted therapy, radiation, and chemotherapy is becoming a standard approach for many cancers [22].”
BackgroundSelf-citationAntibody–drug conjugates in cancer therapy: current landscape, challenges, and future directions
Chen, B., Zheng, X., Wu, J., Chen, G., Yu, J. Q., Xu, Y. X., Wu, W. K. K., Tse, G. M.-K., To, K. F., & Kang, W. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02489-2 · Cited by 131
“These approaches can be further potentiated by biomarker-driven adaptive treatment paradigms, wherein serial molecular profiling (e.g., liquid biopsy or functional imaging) informs real-time modulation of therapeutic regimens in response to evolving resistance dynamics [259–262].”
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Activation of survival pathways can promote cell survival and proliferation in the presence of DNA-damaging agents [49].”
InfluentialRahman, M. A., Jalouli, M., Yadab, M. K., & Al-Zharani, M. M. (2025) · Cancers · doi:10.3390/cancers17040701 · Cited by 82
“Typically, these investigations entail using well-known GBM cell lines, such as U87, U251, and T98G, to assess the harmful effects of chemotherapeutic drugs loaded with nanoparticles.”
Metadata
- Authors
- Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S.
- Affiliations
- GLA University (IN)
- City Of Hope National Medical Center (US)
- Corresponding author
- Singhal, Sharad S.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-07-07
- Volume
- 16
- Issue
- 13
- Pages
- 2478
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC11240358
- OpenAlex
- W4400418891
- Cited by
- 339
- References
- 129
- Citations by year
- 2026: 165 · 2025: 167 · 2024: 6
- FWCI
- 57.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute of the National Institutes of Health (P30CA33572, W81XWH-22-1-0331, HT9425-23-1-0581)
- United States Department of Defense (P30CA33572, W81XWH-22-1-0331, HT9425-23-1-0581)
- City of Hope’s Beckman Research Institute (P30CA33572, W81XWH-22-1-0331, HT9425-23-1-0581)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- chemoresistance, efflux pumps, genetic mutations, tumor microenvironment, targeted therapy, combination therapy, immunotherapy, immune checkpoint inhibitors, adoptive immunotherapy, biomarkers, precision medicine, antitumor immunity, immune evasion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells. https://app.cochat.ai/papers/10.3390/cancers16132478
- The paper
- Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024). Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells. Cancers. https://doi.org/10.3390/cancers16132478
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.